Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Increased Dose Rituximab Plus Maintenance Rituximab for Initial Systemic Treatment of Indolent B-Cell Lymphomas

NCT00895661 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT00895661
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00895661 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Increased Dose Rituximab Plus Maintenance Rituximab for Initial Systemic Treatment of Indolent B-Cell Lymphomas
Lead sponsor
Massachusetts General Hospital
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2009
Completion date
August 31, 2015
Enrollment
40 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell lymphoma, indolent b-cell lymphoma